Skip to main content

Table 3 Clinical & demographic details

From: Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report

 

NMS patients (n = 13)

Cases 1–5 “rapid dose escalators” (n = 5)

Cases 6–13 “non rapid dose escalators” (n = 8)

Mean age, years [95% C.I.]

46.2

47.8

45.2

Male, n (%)

7 (53.8)

2 (40)

5 (62.5)

ICD 10 Diagnosis

F20 Schizophrenia n (%)

7 (53.8)

2 (40)

5 (62.5)

F30 Affective Disorders n (%)

3 (23.1)

2 (40)

1 (12.5)

F0 Organic Mental Disorder n (%)

2 (15.4)

0 (0)

2 (25)

F60 Disorder of Adult Personality & Behaviour n (%)

1 (7.7)

1 (20)

0 (0)

History of alcohol misuse, n (%)

5 (38.5)

2 (40)

3 (37.5)

History of substance misuse, n (%)

4 (30.8)

1 (20)

3 (37.5)

Compulsory Treatment, n (%)

5 (38.5)

2 (40)

3 (37.5)

History of non compliance, n (%)

9 (69.2)

3 (60)

6 (75)

Antipsychotic naïve, n (%)

1 (7.7)

1 (20)

0 (0)

History of extra pyramidal side effects, n (%)

8 (61.5)

2 (40)

6 (75)

Co prescribed oral antidepressant, n (%)

3 (23.1)

2 (40)

1 (12.5)

Co prescribed lithium, n (%)

2 (15.4)

1 (20)

1 (12.5)

Received IM medication, n (%)

5 (38.5)

2 (40)

3 (37.5)

Antipsychotic polypharmacy, n (%)

7 (53.8)

2 (40)

5 (62.5)

Required physical restraint, n (%)

5 (38.5)

2 (40)

3 (37.5)